Does ciltacabtagene autoleucel have a future in multiple myeloma?
Expert analysis clarifies where a CAR-T cell therapy fits in multiple myeloma treatment as newer options emerge, informing clinical decisions.
This Nat Rev Clin Oncol perspective/commentary examines the role of cilta-cel (BCMA-directed CAR-T) in multiple myeloma, likely addressing positioning questions in the context of updated CARTITUDE data and competing bispecific antibody approvals. Abstract not available; commentary/perspective format.
What the study was
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nature Reviews Clinical Oncology
Why it surfaced
Title only retrieved. Nat Rev Clin Oncol commentary on cilta-cel in myeloma — likely high-quality clinical commentary but cannot assess content without abstract. Score capped at 3 (title-only rule). May warrant revisit when abstract available.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.